SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

J.P. Morgan Sees Genmab Outlook Brightening After Drug Trial Data

J.P. Morgan analysts say Genmab’s revenue growth outlook over the next decade looks more certain after strong results in late-stage trials of Rina-S and Epkinly.

GMAB

Related stories